{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:40Z","timestamp":1793041960412,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100016359","name":"Zhongnan Hospital of Wuhan University","doi-asserted-by":"publisher","award":["[grantnumberZNLH201902]"],"award-info":[{"award-number":["[grantnumberZNLH201902]"]}],"id":[{"id":"10.13039\/501100016359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016359","name":"Zhongnan Hospital of Wuhan University","doi-asserted-by":"publisher","award":["grantnumber202021"],"award-info":[{"award-number":["grantnumber202021"]}],"id":[{"id":"10.13039\/501100016359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00277-023-05444-7","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:02:10Z","timestamp":1694638930000},"page":"1069-1083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and\/or refractory multiple myeloma"],"prefix":"10.1007","volume":"103","author":[{"given":"Jiamin","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3745-4199","authenticated-orcid":false,"given":"Fuling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"5444_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA et al (2017) Multiple myeloma. Nature Rev Disease Primers 3:17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46","journal-title":"Nature Rev Disease Primers"},{"key":"5444_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med 335:91\u201397. https:\/\/doi.org\/10.1056\/NEJM199607113350204","journal-title":"N Engl J Med"},{"key":"5444_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375:754\u2013766. https:\/\/doi.org\/10.1056\/NEJMoa1606038","journal-title":"N Engl J Med"},{"key":"5444_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA et al (2015) Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med 372:142\u2013152. https:\/\/doi.org\/10.1056\/NEJMoa1411321","journal-title":"N Engl J Med"},{"key":"5444_CR5","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M et al (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759\u20131769. https:\/\/doi.org\/10.1056\/NEJMoa1112704","journal-title":"N Engl J Med"},{"key":"5444_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J et al (2018) Drug resistance in multiple myeloma. Cancer Treat Rev 70:199\u2013208. https:\/\/doi.org\/10.1016\/j.ctrv.2018.09.001","journal-title":"Cancer Treat Rev"},{"key":"5444_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","volume":"11","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Lin Y, Goldschmidt H et al (2021) KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J 11:116. https:\/\/doi.org\/10.1038\/s41408-021-00507-2","journal-title":"Blood Cancer J"},{"key":"5444_CR8","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A et al (2019) Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33:2266\u20132275. https:\/\/doi.org\/10.1038\/s41375-019-0435-7","journal-title":"Leukemia"},{"key":"5444_CR9","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T et al (2017) Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol: Official J Am Soc Clin Oncol 35:1803\u20131813. https:\/\/doi.org\/10.1200\/JCO.2016.71.3024","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"5444_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"key":"5444_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3:388\u2013398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548","journal-title":"Cancer Discov"},{"key":"5444_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN (2021) CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 18:71\u201384. https:\/\/doi.org\/10.1038\/s41571-020-0427-6","journal-title":"Nat Rev Clin Oncol"},{"key":"5444_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M (2018) Chimeric Antigen Receptor Therapy. N Engl J Med 379:64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169","journal-title":"N Engl J Med"},{"key":"5444_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.intimp.2019.01.010","volume":"70","author":"L Wang","year":"2019","unstructured":"Wang L, Yao R, Zhang L et al (2019) Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. Int Immunopharmacol 70:498\u2013503. https:\/\/doi.org\/10.1016\/j.intimp.2019.01.010","journal-title":"Int Immunopharmacol"},{"key":"5444_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM et al (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44\u201351. https:\/\/doi.org\/10.1016\/j.coi.2015.12.007","journal-title":"Curr Opin Immunol"},{"key":"5444_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D (2020) BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 13:125. https:\/\/doi.org\/10.1186\/s13045-020-00962-7","journal-title":"J Hematol Oncol"},{"key":"5444_CR17","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","volume":"10","author":"C Madry","year":"1998","unstructured":"Madry C, Laabi Y, Callebaut I et al (1998) The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol 10:1693\u20131702. https:\/\/doi.org\/10.1093\/intimm\/10.11.1693","journal-title":"Int Immunol"},{"key":"5444_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1615\/critrevimmunol.v32.i4.10","volume":"32","author":"CM Coquery","year":"2012","unstructured":"Coquery CM, Erickson LD (2012) Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol 32:287\u2013305. https:\/\/doi.org\/10.1615\/critrevimmunol.v32.i4.10","journal-title":"Crit Rev Immunol"},{"key":"5444_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","volume":"24","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Saulep-Easton D, Figgett WA et al (2013) The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 24:203\u2013215. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.04.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"5444_CR20","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3892\/ol.2017.6528","volume":"14","author":"J Pan","year":"2017","unstructured":"Pan J, Sun Y, Zhang N et al (2017) Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance. Oncol Lett 14:2657\u20132662. https:\/\/doi.org\/10.3892\/ol.2017.6528","journal-title":"Oncol Lett"},{"key":"5444_CR21","doi-asserted-by":"publisher","first-page":"215949","DOI":"10.1016\/j.canlet.2022.215949","volume":"553","author":"J Yang","year":"2023","unstructured":"Yang J, Zhou W, Li D et al (2023) BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Cancer Letters 553:215949. https:\/\/doi.org\/10.1016\/j.canlet.2022.215949","journal-title":"Cancer Letters"},{"key":"5444_CR22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.leu.2405048","volume":"22","author":"S Yaccoby","year":"2008","unstructured":"Yaccoby S, Pennisi A, Li X et al (2008) Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22:406\u2013413. https:\/\/doi.org\/10.1038\/sj.leu.2405048","journal-title":"Leukemia"},{"key":"5444_CR23","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"Y-T Tai","year":"2016","unstructured":"Tai Y-T, Acharya C, An G et al (2016) APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127:3225\u20133236. https:\/\/doi.org\/10.1182\/blood-2016-01-691162","journal-title":"Blood"},{"key":"5444_CR24","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","volume":"106","author":"B Bruno","year":"2021","unstructured":"Bruno B, W\u00e4sch R, Engelhardt M et al (2021) European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica 106:2054\u20132065. https:\/\/doi.org\/10.3324\/haematol.2020.276402","journal-title":"Haematologica"},{"key":"5444_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","volume":"19","author":"Y-T Tai","year":"2019","unstructured":"Tai Y-T, Anderson KC (2019) B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther 19:1143\u20131156. https:\/\/doi.org\/10.1080\/14712598.2019.1641196","journal-title":"Expert Opin Biol Ther"},{"key":"5444_CR26","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault MJ, Bishop MR, Rosenblatt J et al (2023) Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv 7:768\u2013777. https:\/\/doi.org\/10.1182\/bloodadvances.2022007210","journal-title":"Blood Adv"},{"key":"5444_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/14712598.2020.1802422","volume":"21","author":"A McMillan","year":"2021","unstructured":"McMillan A, Warcel D, Popat R (2021) Antibody-drug conjugates for multiple myeloma. Expert Opin Biol Ther 21:889\u2013901. https:\/\/doi.org\/10.1080\/14712598.2020.1802422","journal-title":"Expert Opin Biol Ther"},{"key":"5444_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y et al (2021) Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 14:75. https:\/\/doi.org\/10.1186\/s13045-021-01084-4","journal-title":"J Hematol Oncol"},{"key":"5444_CR29","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn P-H et al (2015) \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6:7333. https:\/\/doi.org\/10.1038\/ncomms8333","journal-title":"Nat Commun"},{"key":"5444_CR30","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","volume":"22","author":"E Sanchez","year":"2016","unstructured":"Sanchez E, Gillespie A, Tang G et al (2016) Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Clin Cancer Res: An Official J Am Ass Cancer Res 22:3383\u20133397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2224","journal-title":"Clin Cancer Res: An Official J Am Ass Cancer Res"},{"key":"5444_CR31","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO et al (2019) \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 134:1585\u20131597. https:\/\/doi.org\/10.1182\/blood.2019000050","journal-title":"Blood"},{"key":"5444_CR32","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","volume":"9","author":"D-X Bu","year":"2018","unstructured":"Bu D-X, Singh R, Choi EE et al (2018) Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget 9:25764\u201325780. https:\/\/doi.org\/10.18632\/oncotarget.25359","journal-title":"Oncotarget"},{"key":"5444_CR33","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I et al (2016) T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128:1688\u20131700. https:\/\/doi.org\/10.1182\/blood-2016-04-711903","journal-title":"Blood"},{"key":"5444_CR34","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD et al (2018) T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol: Official J Am Soc Clin Oncol 36:2267\u20132280. https:\/\/doi.org\/10.1200\/JCO.2018.77.8084","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"5444_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman KM, Garrett TE, Evans JW et al (2018) Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Hum Gene Ther 29:585\u2013601. https:\/\/doi.org\/10.1089\/hum.2018.001","journal-title":"Hum Gene Ther"},{"key":"5444_CR36","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y et al (2019) Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 380:1726\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"5444_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-134324","volume":"136","author":"Y Lin","year":"2020","unstructured":"Lin Y, Raje NS, Berdeja JG et al (2020) Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study. Blood 136:26\u201327. https:\/\/doi.org\/10.1182\/blood-2020-134324","journal-title":"Blood"},{"key":"5444_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N et al (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384:705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"5444_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2020-134322","volume":"136","author":"JG Berdeja","year":"2020","unstructured":"Berdeja JG, Raje NS, Siegel DS et al (2020) Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Blood 136:16\u201317. https:\/\/doi.org\/10.1182\/blood-2020-134322","journal-title":"Blood"},{"key":"5444_CR40","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC et al (2023) Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41:2087\u20132097. https:\/\/doi.org\/10.1200\/JCO.22.01365","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"5444_CR41","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B et al (2023) Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med 388:1002\u20131014. https:\/\/doi.org\/10.1056\/NEJMoa2213614","journal-title":"N Engl J Med"},{"key":"5444_CR42","doi-asserted-by":"publisher","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E ChekolAbebe","year":"2022","unstructured":"ChekolAbebe E, YibeltalShiferaw M, TadeleAdmasu F et al (2022) Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Frontiers Immunol 13:991092. https:\/\/doi.org\/10.3389\/fimmu.2022.991092","journal-title":"Frontiers Immunol"},{"key":"5444_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"P Teoh","year":"2021","unstructured":"Teoh P, Chng W (2021) CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J 11:84. https:\/\/doi.org\/10.1038\/s41408-021-00469-5","journal-title":"Blood Cancer J"},{"key":"5444_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"W-H Zhao","year":"2018","unstructured":"Zhao W-H, Liu J, Wang B-Y et al (2018) A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 11:141. https:\/\/doi.org\/10.1186\/s13045-018-0681-6","journal-title":"J Hematol Oncol"},{"key":"5444_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-140243","volume":"136","author":"B Wang","year":"2020","unstructured":"Wang B, Liu J, Zhao W-H et al (2020) Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease\u2013a Single Institution Observation in China. Blood 136:6. https:\/\/doi.org\/10.1182\/blood-2020-140243","journal-title":"Blood"},{"key":"5444_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"B-Y Wang","year":"2019","unstructured":"Wang B-Y, Zhao W-H, Liu J et al (2019) Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM). Blood 134:579. https:\/\/doi.org\/10.1182\/blood-2019-124953","journal-title":"Blood"},{"key":"5444_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"W-H Zhao","year":"2022","unstructured":"Zhao W-H, Wang B-Y, Chen L-J et al (2022) Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol 15:86. https:\/\/doi.org\/10.1186\/s13045-022-01301-8","journal-title":"J Hematol Oncol"},{"key":"5444_CR48","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet (London, England) 398:314\u2013324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet (London, England)"},{"key":"5444_CR49","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG et al (2023) Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol: Official J Am Soc Clin Oncol 41:1265\u20131274. https:\/\/doi.org\/10.1200\/JCO.22.00842","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"5444_CR50","volume-title":"CARTITUDE-1 final results: phase 1b, 2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed, refractory multiple myeloma","author":"N Munshi","year":"2023","unstructured":"Munshi N, Martin T, Usmani SZ et al (2023) CARTITUDE-1 final results: phase 1b, 2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed, refractory multiple myeloma. European Hematology Association 2023 Hybrid Congress, Frankfurt, Germany"},{"key":"5444_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","volume":"42","author":"K Weisel","year":"2022","unstructured":"Weisel K, Martin T, Krishnan A et al (2022) Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician\u2019s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Clin Drug Investig 42:29\u201341. https:\/\/doi.org\/10.1007\/s40261-021-01100-y","journal-title":"Clin Drug Investig"},{"key":"5444_CR52","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","volume":"22","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Lin Y, Cornell RF et al (2022) Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed\/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 22:326\u2013335. https:\/\/doi.org\/10.1016\/j.clml.2021.10.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5444_CR53","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1182\/blood-2022-159169","volume":"140","author":"NW Van De Donk","year":"2022","unstructured":"Van De Donk NW, Agha M, Cohen AD et al (2022) Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up. Blood 140:7536\u20137537. https:\/\/doi.org\/10.1182\/blood-2022-159169","journal-title":"Blood"},{"key":"5444_CR54","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1182\/blood-2021-146072","volume":"138","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Cohen AD, Delforge M et al (2021) Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1\u20133 Prior Lines of Therapy: Updated Results from CARTITUDE-2. Blood 138:3866. https:\/\/doi.org\/10.1182\/blood-2021-146072","journal-title":"Blood"},{"key":"5444_CR55","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos M-V, Cohen YC et al (2023) Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141:219\u2013230. https:\/\/doi.org\/10.1182\/blood.2022015526","journal-title":"Blood"},{"key":"5444_CR56","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K et al (2023) Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 389:335\u2013347. https:\/\/doi.org\/10.1056\/NEJMoa2303379","journal-title":"N Engl J Med"},{"key":"5444_CR57","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","volume":"37","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani SZ, Schecter JM et al (2021) Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin 37:1779\u20131788. https:\/\/doi.org\/10.1080\/03007995.2021.1953456","journal-title":"Curr Med Res Opin"},{"key":"5444_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","volume":"39","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Schecter JM et al (2023) Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin 39:81\u201389. https:\/\/doi.org\/10.1080\/03007995.2022.2139052","journal-title":"Curr Med Res Opin"},{"key":"5444_CR59","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/17474086.2022.2081147","volume":"15","author":"J Davis","year":"2022","unstructured":"Davis J, McGann M, Shockley A et al (2022) Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie\u2019s choice for patients with relapsed refractory multiple myeloma. Expert Rev Hematol 15:473\u2013475. https:\/\/doi.org\/10.1080\/17474086.2022.2081147","journal-title":"Expert Rev Hematol"},{"key":"5444_CR60","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"M-V Mateos","year":"2022","unstructured":"Mateos M-V, Weisel K, De Stefano V et al (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36:1371\u20131376. https:\/\/doi.org\/10.1038\/s41375-022-01531-2","journal-title":"Leukemia"},{"key":"5444_CR61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ et al (2021) Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet (London, England) 398:665\u2013674. https:\/\/doi.org\/10.1016\/S0140-6736(21)01338-6","journal-title":"Lancet (London, England)"},{"key":"5444_CR62","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ et al (2022) Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"5444_CR63","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s12325-023-02551-9","volume":"40","author":"O Landgren","year":"2023","unstructured":"Landgren O, Nadeem O (2023) Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast. Adv Ther 40:3291\u20133303. https:\/\/doi.org\/10.1007\/s12325-023-02551-9","journal-title":"Adv Ther"},{"key":"5444_CR64","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/10781552231154809","volume":"29","author":"K Granger","year":"2023","unstructured":"Granger K, Gaffney KJ, Davis JA (2023) Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed\/refractory multiple myeloma. J Oncol Pharmacy Practice: Official Public Int Soc Oncol Pharm Practitioners 29:722\u2013726. https:\/\/doi.org\/10.1177\/10781552231154809","journal-title":"J Oncol Pharmacy Practice: Official Public Int Soc Oncol Pharm Practitioners"},{"key":"5444_CR65","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Oriol A, Larocca A et al (2021) Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol: Official J Am Soc Clin Oncol 39:757\u2013767. https:\/\/doi.org\/10.1200\/JCO.20.02259","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"5444_CR66","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A et al (2020) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 21:207\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"key":"5444_CR67","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M et al (2019) Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med 381:727\u2013738. https:\/\/doi.org\/10.1056\/NEJMoa1903455","journal-title":"N Engl J Med"},{"key":"5444_CR68","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ (2019) Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 16:372\u2013385. https:\/\/doi.org\/10.1038\/s41571-019-0184-6","journal-title":"Nat Rev Clin Oncol"},{"key":"5444_CR69","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC et al (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997. https:\/\/doi.org\/10.1038\/ncomms3997","journal-title":"Nat Commun"},{"key":"5444_CR70","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood-2019-129582","volume":"134","author":"DJ Green","year":"2019","unstructured":"Green DJ, Pont M, Cowan AJ et al (2019) Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase. Blood 134:1856. https:\/\/doi.org\/10.1182\/blood-2019-129582","journal-title":"Blood"},{"key":"5444_CR71","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.3390\/cancers14133230","volume":"14","author":"B Xie","year":"2022","unstructured":"Xie B, Li Z, Zhou J et al (2022) Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. Cancers 14:3230. https:\/\/doi.org\/10.3390\/cancers14133230","journal-title":"Cancers"},{"key":"5444_CR72","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H et al (2019) A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. The Lancet Haematology 6:e521\u2013e529. https:\/\/doi.org\/10.1016\/S2352-3026(19)30115-2","journal-title":"The Lancet Haematology"},{"key":"5444_CR73","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H et al (2021) A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol 14:161. https:\/\/doi.org\/10.1186\/s13045-021-01170-7","journal-title":"J Hematol Oncol"},{"key":"5444_CR74","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah E, Nam E, Bhuvan V et al (2020) Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun 11:2283. https:\/\/doi.org\/10.1038\/s41467-020-16160-5","journal-title":"Nat Commun"},{"key":"5444_CR75","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/blood-2019-126145","volume":"134","author":"C Fernandez de Larrea","year":"2019","unstructured":"Fernandez de Larrea C, Staehr M, Lopez A et al (2019) Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma. Blood 134:136. https:\/\/doi.org\/10.1182\/blood-2019-126145","journal-title":"Blood"},{"key":"5444_CR76","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF et al (2015) 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:581\u2013590. https:\/\/doi.org\/10.1038\/nm.3838","journal-title":"Nat Med"},{"key":"5444_CR77","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","volume":"3","author":"MJ Frigault","year":"2015","unstructured":"Frigault MJ, Lee J, Basil MC et al (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3:356\u2013367. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0186","journal-title":"Cancer Immunol Res"},{"key":"5444_CR78","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","volume":"27","author":"H Qin","year":"2019","unstructured":"Qin H, Edwards JP, Zaritskaya L et al (2019) Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells. Molecular Therapy: The J Am Soc Gene Therapy 27:1262\u20131274. https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.010","journal-title":"Molecular Therapy: The J Am Soc Gene Therapy"},{"key":"5444_CR79","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","volume":"21","author":"JM Buonato","year":"2022","unstructured":"Buonato JM, Edwards JP, Zaritskaya L et al (2022) Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. Mol Cancer Ther 21:1171\u20131183. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0552","journal-title":"Mol Cancer Ther"},{"key":"5444_CR80","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/leu.2017.57","volume":"31","author":"D Sommermeyer","year":"2017","unstructured":"Sommermeyer D, Hill T, Shamah SM et al (2017) Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia 31:2191\u20132199. https:\/\/doi.org\/10.1038\/leu.2017.57","journal-title":"Leukemia"},{"key":"5444_CR81","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam N, Trinklein ND, Buelow B et al (2020) Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun 11:283. https:\/\/doi.org\/10.1038\/s41467-019-14119-9","journal-title":"Nat Commun"},{"key":"5444_CR82","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G et al (2021) A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137:2890\u20132901. https:\/\/doi.org\/10.1182\/blood.2020008936","journal-title":"Blood"},{"key":"5444_CR83","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1182\/blood-2021-152576","volume":"138","author":"C Li","year":"2021","unstructured":"Li C, Wang D, Song Y et al (2021) A Phase 1\/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and\/or Refractory Multiple Myeloma. Blood 138:547. https:\/\/doi.org\/10.1182\/blood-2021-152576","journal-title":"Blood"},{"key":"5444_CR84","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","volume":"3","author":"KM Dhodapkar","year":"2022","unstructured":"Dhodapkar KM, Cohen AD, Kaushal A et al (2022) Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discovery 3:490\u2013501. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0018","journal-title":"Blood Cancer Discovery"},{"key":"5444_CR85","doi-asserted-by":"publisher","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","volume":"5","author":"JK Bailur","year":"2019","unstructured":"Bailur JK, McCachren SS, Doxie DB et al (2019) Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI insight 5:e127807. https:\/\/doi.org\/10.1172\/jci.insight.127807","journal-title":"JCI insight"},{"key":"5444_CR86","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","volume":"18","author":"M Works","year":"2019","unstructured":"Works M, Soni N, Hauskins C et al (2019) Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide. Mol Cancer Ther 18:2246\u20132257. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1146","journal-title":"Mol Cancer Ther"},{"key":"5444_CR87","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","volume":"9","author":"S Lonial","year":"2022","unstructured":"Lonial S, Popat R, Hulin C et al (2022) Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial. The Lancet Haematology 9:e822\u2013e832. https:\/\/doi.org\/10.1016\/S2352-3026(22)00290-3","journal-title":"The Lancet Haematology"},{"key":"5444_CR88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P et al (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15:47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148","journal-title":"Nat Rev Clin Oncol"},{"key":"5444_CR89","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation"},{"key":"5444_CR90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD et al (2022) Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 12:32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05444-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05444-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05444-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T12:01:48Z","timestamp":1710676908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05444-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["5444"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05444-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors have no conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}